TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The OrthoAccel (OATI) Celerect Device Pivotal Study - Effect of Cyclic Loading (Vibration) on Orthodontic Tooth Movement
Brief Summary: To gather data indicating whether or not the OrthoAccel device speeds tooth movement in people who use orthodontics (braces).


Options:
A: Arm Label: AcceleDent vibrational device; Type: EXPERIMENTAL; Interventions: Device: AcceleDent vibrational device | Arm Label: Sham AcceleDent device; Type: SHAM_COMPARATOR; Interventions: Device: Sham AcceleDent device | Arm Label: Fixed appliance only; Type: ACTIVE_COMPARATOR; Interventions: Other: Fixed appliance only | Intervention Type: DEVICE; Name: AcceleDent vibrational device; Assigned to Arm(s): AcceleDent vibrational device | Intervention Type: DEVICE; Name: Sham AcceleDent device; Assigned to Arm(s): Sham AcceleDent device | Intervention Type: OTHER; Name: Fixed appliance only; Assigned to Arm(s): Fixed appliance only
B: Arm Label: Vibration Device+Fixed Appliance Tx; Type: EXPERIMENTAL; Interventions: Device: Vibration Device | Arm Label: No Vibration Device+Fixed Appliance Tx; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Vibration Device; Assigned to Arm(s): Vibration Device+Fixed Appliance Tx
C: Arm Label: 0.018 bracket slot system; Type: EXPERIMENTAL; Interventions: Device: Orthodontic bracket slot system | Arm Label: 0.022 bracket slot system; Type: ACTIVE_COMPARATOR; Interventions: Device: Orthodontic bracket slot system | Intervention Type: DEVICE; Name: Orthodontic bracket slot system; Assigned to Arm(s): 0.018 bracket slot system, 0.022 bracket slot system
D: Arm Label: OrthoAccel Device; Type: EXPERIMENTAL; Interventions: Device: OrthoAccel Device | Arm Label: Sham Device (inactive device); Type: SHAM_COMPARATOR; Interventions: Device: Sham Device | Intervention Type: DEVICE; Name: OrthoAccel Device; Assigned to Arm(s): OrthoAccel Device | Intervention Type: DEVICE; Name: Sham Device; Assigned to Arm(s): Sham Device (inactive device)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Parallel-arm, Open-label Trial Comparing Degarelix With Goserelin Plus Anti-androgen Flare Protection (Bicalutamide), in Terms of Reduction in International Prostate Symptom Score (IPSS), in Patients With Lower Urinary Tract Symptoms (LUTS) Secondary to Locally Advanced Prostate Cancer
Brief Summary: The purpose of this trial was to see how well a new trial drug (degarelix) worked on lower urinary tract symptoms (also known as LUTS) in prostate cancer patients as compared to how a standard drug hormonal treatment worked on the same symptoms. The advancement/worsening of prostate cancer may be associated with LUTS and the symptoms may impact the ability to urinate normally and thereby the quality of life for these patients.

Patients were randomly selected (like flipping a coin) to receive either degarelix or standard hormone therapy (combination of goserelin and bicalutamide) for a 3 month treatment period. During this period the relief of urinary symptoms was evaluated via a questionnaire filled in by patients and addressing the severity and frequency of their symptoms.


Options:
A: Arm Label: Degarelix; Type: EXPERIMENTAL; Interventions: Drug: Degarelix | Arm Label: Degarelix + Casodex; Type: EXPERIMENTAL; Interventions: Drug: Degarelix, Drug: Casodex | Arm Label: LHRH Agonist + Casodex; Type: ACTIVE_COMPARATOR; Interventions: Drug: Casodex, Drug: LHRH Agonist | Intervention Type: DRUG; Name: Degarelix; Assigned to Arm(s): Degarelix, Degarelix + Casodex | Intervention Type: DRUG; Name: Casodex; Assigned to Arm(s): Degarelix + Casodex, LHRH Agonist + Casodex | Intervention Type: DRUG; Name: LHRH Agonist; Assigned to Arm(s): LHRH Agonist + Casodex
B: Arm Label: Degarelix 240 mg/80 mg; Type: EXPERIMENTAL; Interventions: Drug: Degarelix | Arm Label: Goserelin (3.6 mg) + bicalutamide (50 mg); Type: ACTIVE_COMPARATOR; Interventions: Drug: Goserelin, Drug: Bicalutamide | Intervention Type: DRUG; Name: Degarelix; Assigned to Arm(s): Degarelix 240 mg/80 mg | Intervention Type: DRUG; Name: Goserelin; Assigned to Arm(s): Goserelin (3.6 mg) + bicalutamide (50 mg) | Intervention Type: DRUG; Name: Bicalutamide; Assigned to Arm(s): Goserelin (3.6 mg) + bicalutamide (50 mg)
C: Arm Label: Degarelix 240 mg/80 mg; Type: EXPERIMENTAL; Interventions: Drug: Degarelix | Arm Label: Goserelin (3.6 mg) + bicalutamide (50 mg); Type: ACTIVE_COMPARATOR; Interventions: Drug: Goserelin, Drug: Bicalutamide | Intervention Type: DRUG; Name: Degarelix; Assigned to Arm(s): Degarelix 240 mg/80 mg | Intervention Type: DRUG; Name: Goserelin; Assigned to Arm(s): Goserelin (3.6 mg) + bicalutamide (50 mg) | Intervention Type: DRUG; Name: Bicalutamide; Assigned to Arm(s): Goserelin (3.6 mg) + bicalutamide (50 mg)
D: Arm Label: ASP3550 PART 1 and PART 2; Type: EXPERIMENTAL; Interventions: Drug: degarelix | Arm Label: Goserelin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Goserelin | Intervention Type: DRUG; Name: degarelix; Assigned to Arm(s): ASP3550 PART 1 and PART 2 | Intervention Type: DRUG; Name: Goserelin; Assigned to Arm(s): Goserelin

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Apixaban for Prevention of Acute Ischemic Events - 2 A Phase 3, Randomized, Double-Blind, Evaluation of the Safety and Efficacy of Apixaban In Subjects With a Recent Acute Coronary Syndrome
Brief Summary: The purpose of this study is to determine if apixaban is superior to placebo for preventing cardiovascular death, non-fatal myocardial infarction, or ischemic stroke in subjects with a recent acute coronary syndrome


Options:
A: Arm Label: Rivaroxaban 2.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban, Other: Standard of care for heart failure and coronary artery disease | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: Standard of care for heart failure and coronary artery disease | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban 2.5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: OTHER; Name: Standard of care for heart failure and coronary artery disease; Assigned to Arm(s): Placebo, Rivaroxaban 2.5 mg
B: Arm Label: idarucizumab; Type: EXPERIMENTAL; Interventions: Drug: idarucizumab | Intervention Type: DRUG; Name: idarucizumab; Assigned to Arm(s): idarucizumab
C: Arm Label: Dabigatran dose 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 2 | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Arm Label: Dabigatran dose 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 1 | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Dabigatran dose 1; Assigned to Arm(s): Dabigatran dose 1 | Intervention Type: DRUG; Name: Dabigatran dose 2; Assigned to Arm(s): Dabigatran dose 2
D: Arm Label: Apixaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Apixaban for Prevention of Acute Ischemic Events - 2 A Phase 3, Randomized, Double-Blind, Evaluation of the Safety and Efficacy of Apixaban In Subjects With a Recent Acute Coronary Syndrome
Brief Summary: The purpose of this study is to determine if apixaban is superior to placebo for preventing cardiovascular death, non-fatal myocardial infarction, or ischemic stroke in subjects with a recent acute coronary syndrome


Options:
A: Arm Label: Apixaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: apixaban | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: apixaban; Assigned to Arm(s): 2
C: Arm Label: BioFreedom™ Drug Coated Stent (DCS); Type: EXPERIMENTAL; Interventions: Device: Biofreedom™ Drug Coated Stent (DCS) | Arm Label: Gazelle™ Bare Metal Coronary Stent (BMS); Type: ACTIVE_COMPARATOR; Interventions: Device: Gazelle™ Bare Metal Coronary Stent (BMS) | Intervention Type: DEVICE; Name: Biofreedom™ Drug Coated Stent (DCS); Assigned to Arm(s): BioFreedom™ Drug Coated Stent (DCS) | Intervention Type: DEVICE; Name: Gazelle™ Bare Metal Coronary Stent (BMS); Assigned to Arm(s): Gazelle™ Bare Metal Coronary Stent (BMS)
D: Arm Label: idarucizumab; Type: EXPERIMENTAL; Interventions: Drug: idarucizumab | Intervention Type: DRUG; Name: idarucizumab; Assigned to Arm(s): idarucizumab

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective, Randomized Multicenter Trial of Adjunctive Intravenous Therapy With Sodium-selenite(Selenase®, Double-blinded) and a Procalcitonin Guided Causal Therapy (Open) of Severe Sepsis or Septic Shock.
Brief Summary: Severe sepsis and septic shock are diseases of infectious origin with a high risk of death. The purpose of this study is to determine whether the intravenous application of selenium (given as sodium-selenite) can reduce mortality in patients with severe sepsis or septic shock. Additionally, it is investigated, whether the measurement of procalcitonin - a marker of infection - can be used to guide anti-infectious measures in this disease.


Options:
A: Intervention Type: BEHAVIORAL; Name: No antibiotics if se-procalcitonin is below stated limit; Assigned to Arm(s): N/A
B: Intervention Type: PROCEDURE; Name: PCT measurement; Assigned to Arm(s): N/A
C: Arm Label: PRO-CT group: Experimental; Type: N/A; Interventions: Other: PRO-CT values | Arm Label: Standard group: No intervention; Type: N/A; Interventions: N/A | Intervention Type: OTHER; Name: PRO-CT values; Assigned to Arm(s): PRO-CT group: Experimental
D: Arm Label: SelPCT; Type: ACTIVE_COMPARATOR; Interventions: Drug: sodium-selenite, Procedure: Procalcitonin guided therapy | Arm Label: SelKon; Type: ACTIVE_COMPARATOR; Interventions: Drug: sodium-selenite | Arm Label: PlacPCT; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Procedure: Procalcitonin guided therapy | Arm Label: PlacKon; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: sodium-selenite; Assigned to Arm(s): SelKon, SelPCT | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): PlacKon, PlacPCT | Intervention Type: PROCEDURE; Name: Procalcitonin guided therapy; Assigned to Arm(s): PlacPCT, SelPCT

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective, Randomized Multicenter Trial of Adjunctive Intravenous Therapy With Sodium-selenite(Selenase®, Double-blinded) and a Procalcitonin Guided Causal Therapy (Open) of Severe Sepsis or Septic Shock.
Brief Summary: Severe sepsis and septic shock are diseases of infectious origin with a high risk of death. The purpose of this study is to determine whether the intravenous application of selenium (given as sodium-selenite) can reduce mortality in patients with severe sepsis or septic shock. Additionally, it is investigated, whether the measurement of procalcitonin - a marker of infection - can be used to guide anti-infectious measures in this disease.


Options:
A: Arm Label: SelPCT; Type: ACTIVE_COMPARATOR; Interventions: Drug: sodium-selenite, Procedure: Procalcitonin guided therapy | Arm Label: SelKon; Type: ACTIVE_COMPARATOR; Interventions: Drug: sodium-selenite | Arm Label: PlacPCT; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Procedure: Procalcitonin guided therapy | Arm Label: PlacKon; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: sodium-selenite; Assigned to Arm(s): SelKon, SelPCT | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): PlacKon, PlacPCT | Intervention Type: PROCEDURE; Name: Procalcitonin guided therapy; Assigned to Arm(s): PlacPCT, SelPCT
B: Arm Label: PCT guided; Type: EXPERIMENTAL; Interventions: Procedure: Earlier therapeutic changes regarding infection | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Procedure: Earlier therapeutic changes regarding infection | Intervention Type: PROCEDURE; Name: Earlier therapeutic changes regarding infection; Assigned to Arm(s): Control, PCT guided
C: Arm Label: Procalcitonin-guided group; Type: N/A; Interventions: Other: Literature search | Arm Label: Routine practice group; Type: N/A; Interventions: Other: Literature search | Intervention Type: OTHER; Name: Literature search; Assigned to Arm(s): Procalcitonin-guided group, Routine practice group
D: Intervention Type: PROCEDURE; Name: PCT measurement; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Restricting the Use of AS-AQ Combination Therapy to Malaria Cases Confirmed by a Dipstick Test: A Cluster Randomised Control Trial
Brief Summary: Effective use of Rapid Diagnostic Test (RDT) and artemisinin-based combination therapy (ACT) depends on the accuracy and safety of RDT based treatment practices and on factors related to the health delivery system. We propose to study the accuracy and safety of RDT based diagnosis and treatment of febrile illness, health system determinants of effective use of RDTs and the public health outcomes of RDT based ACT for malaria.A cluster randomised trial of RDT based versus clinical judgment based treatment of febrile illness on the incidence of malaria in \<48 month old children will be conducted. Health Centres will be randomly allocated to RDT based treatment or clinical judgment based treatment arm and children under 2years of age from the catchment area of each health centre will be followed for 2 years. The cost effectiveness of RDT based approach will be compare with the clinical judgement based treatment.


Options:
A: Intervention Type: DEVICE; Name: Rapid diagnostic test for malaria; Assigned to Arm(s): N/A
B: Intervention Type: DEVICE; Name: Rapid Diagnostic Test for P. falciparum malaria; Assigned to Arm(s): N/A
C: Arm Label: RDT+ACT group; Type: EXPERIMENTAL; Interventions: Device: RDT, Other: Clinical Judgement as basis for treatment of malaria with ACT | Arm Label: Clinical judgement+ACT group; Type: ACTIVE_COMPARATOR; Interventions: Device: RDT, Other: Clinical Judgement as basis for treatment of malaria with ACT | Intervention Type: DEVICE; Name: RDT; Assigned to Arm(s): Clinical judgement+ACT group, RDT+ACT group | Intervention Type: OTHER; Name: Clinical Judgement as basis for treatment of malaria with ACT; Assigned to Arm(s): Clinical judgement+ACT group, RDT+ACT group
D: Arm Label: Observation; Type: N/A; Interventions: Drug: Artesunate + Amodiaquine Fixed Dose Combination (CoArsucam) | Intervention Type: DRUG; Name: Artesunate + Amodiaquine Fixed Dose Combination (CoArsucam); Assigned to Arm(s): Observation

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Smoking Cessation With Varenicline (Champix) and Integrated Voice Response Technology (IVR)
Brief Summary: The goal of this study is to provide you with an effective treatment for reducing the physical and emotional stress that can occur during the early phase of being without cigarettes. It is our hope that this treatment will help you to stay smoke-free. You will receive counseling and a supply of Champix, a medication to help suppress the symptoms of nicotine withdrawal.

Purpose: To assess the effect of extended Integrated Voice Response (IVR) on smoking cessation after varenicline (Champix) and IVR treatment Hypothesis: There will be significant increase in participants who do not smoke at 1 year if extended IVR is used after 12 weeks of varenicline (Champix) and IVR treatment.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Extended IVR (integrated voice response technology), Drug: Varenicline (Champix), Behavioral: IVR treatment | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline (Champix), Behavioral: IVR treatment | Intervention Type: BEHAVIORAL; Name: Extended IVR (integrated voice response technology); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Varenicline (Champix); Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: IVR treatment; Assigned to Arm(s): 1, 2
B: Arm Label: Sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Sugar pill, Varenicline
C: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1 Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: 2 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): 1 Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Smoking Cessation With Varenicline (Champix) and Integrated Voice Response Technology (IVR)
Brief Summary: The goal of this study is to provide you with an effective treatment for reducing the physical and emotional stress that can occur during the early phase of being without cigarettes. It is our hope that this treatment will help you to stay smoke-free. You will receive counseling and a supply of Champix, a medication to help suppress the symptoms of nicotine withdrawal.

Purpose: To assess the effect of extended Integrated Voice Response (IVR) on smoking cessation after varenicline (Champix) and IVR treatment Hypothesis: There will be significant increase in participants who do not smoke at 1 year if extended IVR is used after 12 weeks of varenicline (Champix) and IVR treatment.


Options:
A: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Extended IVR (integrated voice response technology), Drug: Varenicline (Champix), Behavioral: IVR treatment | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline (Champix), Behavioral: IVR treatment | Intervention Type: BEHAVIORAL; Name: Extended IVR (integrated voice response technology); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Varenicline (Champix); Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: IVR treatment; Assigned to Arm(s): 1, 2
C: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo tablet is made of lactose | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo tablet is made of lactose; Assigned to Arm(s): control group
D: Arm Label: Scheduled Gradual Reduction + Varenicline; Type: EXPERIMENTAL; Interventions: Other: Scheduled Gradual Reduction + Varenicline | Arm Label: Scheduled Gradual Reduction + Placebo Drug; Type: EXPERIMENTAL; Interventions: Other: Scheduled Gradual Reduction + Placebo Drug | Arm Label: Basic Advice + Varenicline; Type: EXPERIMENTAL; Interventions: Other: Basic Advice + Varenicline | Arm Label: Basic Advice + Placebo Drug; Type: PLACEBO_COMPARATOR; Interventions: Other: Basic Advice + Placebo Drug | Intervention Type: OTHER; Name: Scheduled Gradual Reduction + Varenicline; Assigned to Arm(s): Scheduled Gradual Reduction + Varenicline | Intervention Type: OTHER; Name: Scheduled Gradual Reduction + Placebo Drug; Assigned to Arm(s): Scheduled Gradual Reduction + Placebo Drug | Intervention Type: OTHER; Name: Basic Advice + Varenicline; Assigned to Arm(s): Basic Advice + Varenicline | Intervention Type: OTHER; Name: Basic Advice + Placebo Drug; Assigned to Arm(s): Basic Advice + Placebo Drug

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Smoking Cessation With Varenicline (Champix) and Integrated Voice Response Technology (IVR)
Brief Summary: The goal of this study is to provide you with an effective treatment for reducing the physical and emotional stress that can occur during the early phase of being without cigarettes. It is our hope that this treatment will help you to stay smoke-free. You will receive counseling and a supply of Champix, a medication to help suppress the symptoms of nicotine withdrawal.

Purpose: To assess the effect of extended Integrated Voice Response (IVR) on smoking cessation after varenicline (Champix) and IVR treatment Hypothesis: There will be significant increase in participants who do not smoke at 1 year if extended IVR is used after 12 weeks of varenicline (Champix) and IVR treatment.


Options:
A: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo tablet is made of lactose | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo tablet is made of lactose; Assigned to Arm(s): control group
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Extended IVR (integrated voice response technology), Drug: Varenicline (Champix), Behavioral: IVR treatment | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline (Champix), Behavioral: IVR treatment | Intervention Type: BEHAVIORAL; Name: Extended IVR (integrated voice response technology); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Varenicline (Champix); Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: IVR treatment; Assigned to Arm(s): 1, 2
C: Arm Label: Standard Arm (Arm A); Type: ACTIVE_COMPARATOR; Interventions: Other: TOBACCO CIGARETTES | Arm Label: Intervention Arm (Arm B); Type: ACTIVE_COMPARATOR; Interventions: Other: COMBUSTION-FREE NICOTINE DELIVERY SYSTEMS (C-F NDS) | Intervention Type: OTHER; Name: TOBACCO CIGARETTES; Assigned to Arm(s): Standard Arm (Arm A) | Intervention Type: OTHER; Name: COMBUSTION-FREE NICOTINE DELIVERY SYSTEMS (C-F NDS); Assigned to Arm(s): Intervention Arm (Arm B)
D: Arm Label: 1 Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: 2 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): 1 Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 Placebo

Answer: B